Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imsidolimab - AnaptysBio

Next Previous
Drug Profile

Imsidolimab - AnaptysBio

Alternative Names: ANB 019

Latest Information Update: 11 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Generalised pustular psoriasis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pustular psoriasis

Highest Development Phases

  • Phase III Generalised pustular psoriasis
  • Phase II Acneiform eruptions; Ichthyosis
  • No development reported Palmoplantar pustulosis
  • Discontinued Acne vulgaris; Hidradenitis suppurativa

Most Recent Events

  • 09 Oct 2023 AnaptysBio plans to file a biologics license application (BLA) for Generalized Pustular Psoriasis with the US FDA by Q3 2024.
  • 09 Oct 2023 Adverse events and efficacy data from the phase III GEMINI1 trial in Generalised pustular psoriasis released by AnaptysBio
  • 17 Aug 2023 AnaptysBio completes the phase III GEMINI1 trial in Generalised pustular psoriasis in Australia, Georgia, Germany, South Korea, Malaysia, Morocco, Poland, Romania, Slovakia, Spain, Taiwan, Thailand, Tunisia, Turkey, USA (IV) (NCT05352893) (EudraCT2021-001447-27)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top